Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
monoclonal antibody
|
| gptkbp:administrativeDivision |
every 2 weeks
|
| gptkbp:approves |
gptkb:FDA
2017 |
| gptkbp:chemicalFormula |
C6424H9920N1716O1984S44
|
| gptkbp:clinicalTrials |
Phase 1
oncology Phase 2 Phase 3 ESMO guidelines JAVELIN Bladder 100 JAVELIN Gastric 100 JAVELIN Merkel 200 JAVELIN Ovarian 100 JAVELIN Solid Tumor NCCN_guidelines |
| gptkbp:developedBy |
gptkb:Pfizer
Merck KGaA |
| gptkbp:hasPopulation |
adults
pediatric patients |
| gptkbp:historical_analysis |
ongoing studies
real-world evidence studies completed studies phase 4 studies |
| https://www.w3.org/2000/01/rdf-schema#label |
Avelumab
|
| gptkbp:isATypeOf |
1432020-66-0
|
| gptkbp:issuedBy |
intravenous infusion
|
| gptkbp:lastProduced |
gptkb:USA
Europe |
| gptkbp:mandates |
metastatic cancer
advanced cancer unresectable cancer |
| gptkbp:marketedAs |
gptkb:Bavencio
more than 60 countries |
| gptkbp:operates_in |
L01XC17
|
| gptkbp:patentStatus |
licensed
patented |
| gptkbp:researchAreas |
cancer treatment
immunotherapy |
| gptkbp:route |
IV
systemic |
| gptkbp:safetyFeatures |
generally well tolerated
|
| gptkbp:sideEffect |
fatigue
nausea diarrhea rash infusion-related reactions |
| gptkbp:targets |
gptkb:PD-L1
|
| gptkbp:triggerType |
immune checkpoint inhibitor
|
| gptkbp:usedFor |
treatment of urothelial carcinoma
treatment_of_Merkel_cell_carcinoma |
| gptkbp:weight |
146 kDa
|
| gptkbp:worksWith |
radiation therapy
chemotherapy |